The landscape of cancer therapy has undergone a dramatic evolution in recent decades, shifting from broad-spectrum cytotoxic agents to highly targeted approaches. Among these advancements, antibody-drug conjugates (ADCs) have emerged as a promising class of therapeutics, offering the potential to selectively deliver potent cytotoxic payloads to tumor cells while minimizing off-target toxicity. This essay will explore the recent advances in ADC technology, highlighting key developments in antibody engineering, linker design, payload selection, and clinical applications, while also recognizing the contributions of prominent researchers in the field.

Bladder cancer, a prevalent malignancy affecting the urinary system, poses a significant global health burden. Despite advancements in surgical techniques, chemotherapy, and immunotherapy, a considerable number of patients experience recurrence and progression, underscoring the need for novel therapeutic strategies. Recent developments in RNA interference (RNAi) technology, particularly the use of small activating RNAs (saRNAs), have shown promise in targeting oncogenic pathways and restoring tumor suppressor gene expression. Ractigen Therapeutics, a pioneering biotechnology company, has been at the forefront of developing saRNA-based therapies, with preclinical and clinical studies indicating their potential efficacy in bladder cancer treatment. This essay aims to explore the emerging role of Ractigen's saRNA therapy in bladder cancer, analyzing its mechanism of action, preclinical and clinical evidence, and future perspectives.